Ticker Details
Heron Therapeutics, Inc. Heron Therapeutics Inc is a biotechnology company, developing products to address unmet medical needs. It is developing novel, patient-focused solutions that apply its science and technologies to already-approved pharmacological agents.
IPO Date:	January 23, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$154.49M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.37 | 3.07%
Avg Daily Range (30 D):	$0.03 | 3.01%
Avg Daily Range (90 D):	$0.03 | 2.77%

Institutional Daily Volume
Avg Daily Volume:	1.28M
Avg Daily Volume (30 D):	1.83M
Avg Daily Volume (90 D):	1.62M

Trade Size
Avg Trade Size (Sh.):	166
Avg Trade Size (Sh.) (30 D):	314
Avg Trade Size (Sh.) (90 D):	334

Institutional Trades
Total Institutional Trades:	3,472
Avg Institutional Trade:	$1.58M
Avg Institutional Trade (30 D):	$1.88M
Avg Institutional Trade (90 D):	$1.44M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.03M
Avg Closing Trade (30 D):	$1.57M
Avg Closing Trade (90 D):	$1.57M
Avg Closing Volume:	180.87K

News

Oct 29, 2025 @ 9:58 PM Heron Therapeutics Announces Appointment of Thomas... Source: Craig Collard

Oct 29, 2024 @ 8:05 PM Heron Therapeutics to Report Third Quarter 2024 Fi... Source: Prnewswire

Sep 17, 2024 @ 10:00 AM Chemotherapy Induced Nausea and Vomiting Treatment... Source: Fact.Mr

Jul 2, 2024 @ 12:43 PM Merck (MRK) Gets Exclusive Rights to Opevesostat F... Source: Zacks Equity Research

Jul 1, 2024 @ 2:31 PM FDA Rejects Rocket's (RCKT) Gene Therapy BLA for R... Source: Zacks Equity Research

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.12	$-.01	$-.12
Diluted EPS	$-.12	$-.01	$-.12
Revenue	$154.9M	$40.59M	$154.9M
Gross Profit	$113.56M	$29.47M	$113.56M
Net Income / Loss	$-20.2M	$-2.95M	$-20.2M
Operating Income / Loss	$-2.54M	$.04M	$-2.54M
Cost of Revenue	$41.35M	$11.12M	$41.35M
Net Cash Flow	$2.85M	$-14.42M	$2.85M
PE Ratio

Splits
Jan 13, 2014	1:20
May 25, 2007	1:4